Congential Heart Disease Pipeline Review 2021

Congenital heart disease or congenital heart defect, is abnormality of heart present from birth. This disease can affect: the heart valves, the heart walls, and the blood vessels. There are various types of congenital heart defects. The symptoms of this disease can range from simple conditions which don’t cause symptoms to complex problems that cause severe, life-threatening symptoms.

According to the data published by Centers for Disease Control and Prevention, there are presently 1 million adults and 1 million children in the U.S. suffering from congenital heart defects. However, over the past few decades, treatments and follow-up care for defects have improved drastically, so almost all children with defects heart survive into adulthood.

Approximately 70% of pipeline drugs for congential heart disease are in phase 2 clinical stage. Several government institutes and research organizations are conducting clinical trials combined with pharmaceutical companies to treat and prevent congential heart disease.

Report Description

The report on congential heart disease- Pipeline Review, 2020 provides comprehensive information regarding drugs in the pipeline by indication or molecule for congential heart disease. The report provides a complete analysis of the stage of development, mechanism of action (MoA), drug target route of administration (RoA) and molecule type. The report helps in tracking and identifying emerging players in the market and their portfolios enhance decision-making capabilities and assists companies in developing growth strategies by providing a complete overview of R&D activities.

Report Scope

• Assessment of pipeline products based on various stages of devolvement.
• Provides an overview of the global therapeutic landscape of Congential Heart Disease (Infectious Disease).
• Provides comprehensive details of pipeline products based upon companies and universities/research institutes overviews
• The report provides descriptive features regarding drug profiles for the pipeline products which comprise, product description, R&D brief, descriptive licensing and collaboration details, MoA & other developmental activities.
• Latest news, articles, press-release, and related conferences

• Provides detailed analysis regarding significant competitor and insights to formulate effective R&D development strategies
• Create effective counter-strategies to gain competitive advantage and identify emerging players with a potentially strong product portfolio
• Build strategic initiatives by understanding the focus areas of leading companies
• Identify strategies to diversify R&D focus to drive the growth in business and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Analysis of the reason behind the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
• Provides detailed analysis regarding significant competitor and insights to formulate effective R&D development strategies
• Create effective counter-strategies to gain competitive advantage and identify emerging players with a potentially strong product portfolio
• Build strategic initiatives by understanding the focus areas of leading companies
• Identify strategies to diversify R&D focus to drive the growth in business and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Analysis of the reason behind the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

1. Introduction

• Objectives of the Study
• Definition
• Report Overview
• Congential Heart Disease Overview

2. Executive Summary
3. Congential Heart Disease: Pipeline Assessment

• Company Overview
• Product Description
• Status
• Phase
• Study Design
• Route of Administration
• Indication       
• Condition        
• NCT Number              
• Sponsor          
• Collaborator   
• Brief Title         
• Study Start Date         
• Study completion (Estimated/Actual)
• Study Completion Date
• Enrollment     
• Research Location (Listed Location Countries)

4. Congential Heart Disease: Analysis on Dormant & Discontinued Pipeline Candidates

• Overview
• Product Description
• Reason for Discontinuation

5. Congential Heart Disease: Additional Key Insights

• Epidemiology Overview: Congential Heart Disease

6. Congential Heart Disease: Press Releases, Latest News and Conference Details

Note:

• Table of Content is tentative and subject to change as the research progresses
• The drug candidates are included as examples in the pipeline when this ToC was designed and their status might have changed since then.